AUTHORS
Xiaojian Zhu, MD, Shiping Jiao, MD, PhD2, Wei Mu, PhD3, Lijun Jiang4, Cheng He, PhD5, Xing Chen6, Wenjing Gao7, Jingchao Liu8
AFFILIATIONS
1 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
2 TCRX (KeShiHua) Therapeutics Co, Ltd., Nanjing, Jiangsu, China
3 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
4 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
5 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
6 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
7 TCRX (KeShiHua) Therapeutics Co, Ltd., Nanjing, Jiangsu, China
8 TCRX (KeShiHua) Therapeutics Co, Ltd., Nanjing, Jiangsu, China
ABSTRACT
Background: KSV01 is an optimized, third-generation lentiviral vector (LVV) engineered for the selective in vivo transduction of circulating T cells, thereby generating anti-CD19 CAR-T cells following intravenous administration. The off-the-shelf nature of KSV01 obviates the need for both leukapheresis and lymphodepleting chemotherapy. Unlike previously reported LVV-based in vivo CAR-T therapies—which have been associated with significant infusion-related reactions (IRRs) requiring prophylactic corticosteroid intervention—KSV01 incorporates an immuno-quiescent design intended to mitigate the characteristic early-phase cytokine surge. Here, we present preliminary results from the first-in-human phase 1 trial evaluating KSV01 in pts with r/r DLBCL (NCT07260812).
Methods: Eligible patients were aged 18–65 years with relapsed/refractory DLBCL (2016 WHO classification) after ≥1 prior line of therapy, ECOG PS 0–1, and adequate end-organ function. This is a 3+3 dose-escalation study with accelerated titration across three dose levels (DL1: 0.2×108, DL2: 0.6×108, DL3: 2×108 TU). KSV01 was administered as a single intravenous infusion without corticosteroid prophylaxis. Primary endpoints were dose-limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and laboratory abnormalities, graded according to the Common Terminology Criteria for Adverse Events, version 5.0 (CTCAE v5.0).
Results: As of the July 31, 2026 cutoff, five eligible pts (age 49–62) were enrolled. Disease status included primary refractory disease in 2 pts (Pts 2, 5) and early relapse (<6 mo post-frontline R-CHOP; Pts 1, 3, 4). Cell-of-origin subtyping revealed germinal center B-cell (GCB) subtype in Pt 2, non-GCB subtype in Pts 3, 4, and 5, and was indeterminate in Pt 1. Baseline characteristics included bone marrow involvement (Pt 1) and extranodal involvements (Pts 2–4). Regarding prior therapies, Pts 1–4 had received 8 cycles of R-CHOP. Pt 5 had received 5 cycles of Pola-R-CHP, achieving stable disease after 4 cycles and progressing thereafter.
All pts experienced TEAEs; no DLTs occurred. IRRs occurred in 2 pts (1 each, DL2/DL3), all Gr 1 transient hypotension without associated clinical sequelae. Notably, no transaminase elevations were observed within 3 days post-infusion. No CRS or ICANS occurred. Gr ≥3 AEs were predominantly hematologic, occurring mostly within 7 days: leukopenia (1/5), neutropenia (2/5), and lymphopenia (3/5). Non-hematologic toxicity included Gr ≥3 gamma-glutamyl transferase (GGT) elevation in 3/5 pts, temporally coinciding with in vivo CAR-T expansion.
Among the 4 efficacy-evaluable pts, all achieved objective response. Pt 1 (DL1) and Pt 2 (DL2) achieved complete response (CR) at 6 weeks post-infusion and sustained through 6 months; Pt 1 remained bone marrow minimal residue disease (MRD)-negative through 6 months, tested by multiparameter flow cytometry with a sensitivity threshold of 10-4. Pts 3 and 4 (both DL2) achieved confirmed partial response (PR) at 6 weeks post-infusion and sustained at 3-month assessment. All responses remain ongoing.
The expansion and persistence of KSV01-transduced in vivo CAR-T cells were evaluated by quantitative polymerase chain reaction (qPCR) and flow cytometry in all pts. Peak CAR transgene copy number ranged 0–39823.03 copies/μg gDNA, corresponding to 0%–60.88% of CD3? T cells (up to 2408 cells/μL). The time to peak expansion (Tmax) exhibited an inverse dose-dependent manner: 21 days at DL1 versus median 15.5 days (range, 14–20) at DL2/DL3. In Pt 3, peripheral transgene remained undetectable (limit of detection: 50 copies/μg gDNA) throughout follow-up despite confirmed PR and ongoing B-cell aplasia through 3 months.
Baseline peripheral B cells were undetectable in all 5 pts. Aplasia persisted through 3 months in Pts 1–3, with recovery at 6 months in Pts 1 and 2. Pts 4 and 5 had intermittent low-level B cells (<5 cells/μL) within 28 days; Pt 4 showed low recovery (2.5 cells/μL) at day 42.
Conclusions: Preliminary results from this first-in-human phase 1 study demonstrate that KSV01, an off-the-shelf in vivo CAR-T therapy, exhibits efficacy and manageable toxicity in r/r DLBCL at low dose levels. Further data are needed to evaluate durability of response and safety at higher doses.
DISCLOSURES
Xiaojian Zhu, MD: No relevant conflicts of interest to declare.